-
1
-
-
0029947568
-
Enhancement of antitumor immunity by CTLA-4 blockade
-
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-1736.
-
(1996)
Science.
, vol.271
, Issue.5256
, pp. 1734-1736
-
-
Leach, D.R.1
Krummel, M.F.2
Allison, J.P.3
-
2
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
-
(2012)
Nat Rev Cancer.
, vol.12
, Issue.4
, pp. 252-264
-
-
Pardoll, D.M.1
-
3
-
-
0034596948
-
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
-
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7): 1027-1034.
-
(2000)
J Exp Med.
, vol.192
, Issue.7
, pp. 1027-1034
-
-
Freeman, G.J.1
Long, A.J.2
Iwai, Y.3
-
4
-
-
84940403833
-
PD-1 blockers
-
Wolchok JD. PD-1 Blockers. Cell. 2015;162(5):937.
-
(2015)
Cell
, vol.162
, Issue.5
, pp. 937
-
-
Wolchok, J.D.1
-
5
-
-
0028791059
-
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4
-
Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270(5238): 985-988.
-
(1995)
Science.
, vol.270
, Issue.5238
, pp. 985-988
-
-
Waterhouse, P.1
Penninger, J.M.2
Timms, E.3
-
6
-
-
0028867420
-
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
-
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5): 541-547.
-
(1995)
Immunity.
, vol.3
, Issue.5
, pp. 541-547
-
-
Tivol, E.A.1
Borriello, F.2
Schweitzer, A.N.3
Lynch, W.P.4
Bluestone, J.A.5
Sharpe, A.H.6
-
7
-
-
0033180181
-
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor
-
Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11 (2):141-151.
-
(1999)
Immunity.
, vol.11
, Issue.2
, pp. 141-151
-
-
Nishimura, H.1
Nose, M.2
Hiai, H.3
Minato, N.4
Honjo, T.5
-
8
-
-
0035846991
-
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
-
Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502): 319-322.
-
(2001)
Science.
, vol.291
, Issue.5502
, pp. 319-322
-
-
Nishimura, H.1
Okazaki, T.2
Tanaka, Y.3
-
9
-
-
84864052441
-
Management of immune-related adverse events and kinetics of response with ipilimumab
-
Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30 (21):2691-2697.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.21
, pp. 2691-2697
-
-
Weber, J.S.1
Kähler, K.C.2
Hauschild, A.3
-
10
-
-
85009968823
-
Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies
-
Byun DJ,Wolchok JD, Rosenberg LM, GirotraM. Cancer immunotherapy-immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13(4): 195-207.
-
(2017)
Nat Rev Endocrinol.
, vol.13
, Issue.4
, pp. 195-207
-
-
Byun, D.J.1
Wolchok, J.D.2
Rosenberg, L.M.3
Girotra, M.4
-
13
-
-
77958110812
-
Conductingmeta-analyses in R with the metafor package
-
ViechtbauerW. Conductingmeta-analyses in R with the metafor package. J Stat Softw. 2010;36(3): 1-48.
-
(2010)
J Stat Softw.
, vol.36
, Issue.3
, pp. 1-48
-
-
Viechtbauer, W.1
-
14
-
-
84962038946
-
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial
-
(10030)
-
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387 (10030):1837-1846.
-
(2016)
Lancet.
, vol.387
, pp. 1837-1846
-
-
Fehrenbacher, L.1
Spira, A.2
Ballinger, M.3
-
15
-
-
84959577118
-
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
-
(10031)
-
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031): 1909-1920.
-
(2016)
Lancet.
, vol.387
, pp. 1909-1920
-
-
Rosenberg, J.E.1
Hoffman-Censits, J.2
Powles, T.3
-
16
-
-
84951126341
-
Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer
-
Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34): 4015-4022.
-
(2015)
J Clin Oncol.
, vol.33
, Issue.34
, pp. 4015-4022
-
-
Hamanishi, J.1
Mandai, M.2
Ikeda, T.3
-
17
-
-
84964779633
-
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial
-
Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717-726.
-
(2016)
Lancet Oncol.
, vol.17
, Issue.6
, pp. 717-726
-
-
Muro, K.1
Chung, H.C.2
Shankaran, V.3
-
18
-
-
84929481481
-
Pembrolizumab versus ipilimumab in advanced melanoma
-
Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26): 2521-2532.
-
(2015)
N Engl J Med.
, vol.372
, Issue.26
, pp. 2521-2532
-
-
Robert, C.1
Schachter, J.2
Long, G.V.3
-
19
-
-
84936147067
-
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
-
(2015)
N Engl J Med.
, vol.373
, Issue.1
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
-
20
-
-
84950117835
-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial
-
(10027)
-
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027): 1540-1550.
-
(2016)
Lancet.
, vol.387
, pp. 1540-1550
-
-
Herbst, R.S.1
Baas, P.2
Kim, D.W.3
-
21
-
-
85016509105
-
Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab
-
Weber J, Gibney G, Kudchadkar R, et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res. 2016;4(4): 345-353.
-
(2016)
Cancer Immunol Res.
, vol.4
, Issue.4
, pp. 345-353
-
-
Weber, J.1
Gibney, G.2
Kudchadkar, R.3
-
22
-
-
84946607195
-
Nivolumab versus everolimus in advanced renal-cell carcinoma
-
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19): 1803-1813.
-
(2015)
N Engl J Med.
, vol.373
, Issue.19
, pp. 1803-1813
-
-
Motzer, R.J.1
Escudier, B.2
McDermott, D.F.3
-
23
-
-
84938205998
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial
-
Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8): 908-918.
-
(2015)
Lancet Oncol.
, vol.16
, Issue.8
, pp. 908-918
-
-
Ribas, A.1
Puzanov, I.2
Dummer, R.3
-
24
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372 (21):2018-2028.
-
(2015)
N Engl J Med.
, vol.372
, Issue.21
, pp. 2018-2028
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
-
25
-
-
84969988424
-
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial
-
Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956-965.
-
(2016)
Lancet Oncol.
, vol.17
, Issue.7
, pp. 956-965
-
-
Seiwert, T.Y.1
Burtness, B.2
Mehra, R.3
-
26
-
-
84945554100
-
Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors
-
Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21(19): 4286-4293.
-
(2015)
Clin Cancer Res.
, vol.21
, Issue.19
, pp. 4286-4293
-
-
Patnaik, A.1
Kang, S.P.2
Rasco, D.3
-
27
-
-
84944937210
-
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
-
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639.
-
(2015)
N Engl J Med.
, vol.373
, Issue.17
, pp. 1627-1639
-
-
Borghaei, H.1
Paz-Ares, L.2
Horn, L.3
-
28
-
-
84929572937
-
Nivolumab formetastatic renal cell carcinoma: Results of a randomized phase II trial
-
Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab formetastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430-1437.
-
(2015)
J Clin Oncol.
, vol.33
, Issue.13
, pp. 1430-1437
-
-
Motzer, R.J.1
Rini, B.I.2
McDermott, D.F.3
-
29
-
-
84983652291
-
Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer
-
Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2980-2987.
-
(2016)
J Clin Oncol.
, vol.34
, Issue.25
, pp. 2980-2987
-
-
Gettinger, S.1
Rizvi, N.A.2
Chow, L.Q.3
-
30
-
-
84931083080
-
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial
-
Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-384.
-
(2015)
Lancet Oncol.
, vol.16
, Issue.4
, pp. 375-384
-
-
Weber, J.S.1
D'Angelo, S.P.2
Minor, D.3
-
31
-
-
84925222119
-
Nivolumab in previously untreated melanoma without BRAF mutation
-
Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4): 320-330.
-
(2015)
N Engl J Med.
, vol.372
, Issue.4
, pp. 320-330
-
-
Robert, C.1
Long, G.V.2
Brady, B.3
-
32
-
-
84908354848
-
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial
-
Robert C, Ribas A,Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109-1117.
-
(2014)
Lancet.
, vol.384
, Issue.9948
, pp. 1109-1117
-
-
Robert, C.1
Ribas, A.2
Wolchok, J.D.3
-
33
-
-
84936791837
-
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
-
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-135.
-
(2015)
N Engl J Med.
, vol.373
, Issue.2
, pp. 123-135
-
-
Brahmer, J.1
Reckamp, K.L.2
Baas, P.3
-
34
-
-
84978198904
-
Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study
-
Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21): 2460-2467.
-
(2016)
J Clin Oncol.
, vol.34
, Issue.21
, pp. 2460-2467
-
-
Nanda, R.1
Chow, L.Q.2
Dees, E.C.3
-
35
-
-
84971620553
-
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial
-
Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883-895.
-
(2016)
Lancet Oncol.
, vol.17
, Issue.7
, pp. 883-895
-
-
Antonia, S.J.1
Lopez-Martin, J.A.2
Bendell, J.3
-
36
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
-
(2013)
N Engl J Med.
, vol.369
, Issue.2
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
-
37
-
-
84924901863
-
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial
-
Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3): 257-265.
-
(2015)
Lancet Oncol.
, vol.16
, Issue.3
, pp. 257-265
-
-
Rizvi, N.A.1
Mazieres, J.2
Planchard, D.3
-
38
-
-
77954899030
-
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates
-
Brahmer JR, Drake CG,Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19): 3167-3175.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.19
, pp. 3167-3175
-
-
Brahmer, J.R.1
Drake, C.G.2
Wollner, I.3
-
39
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26): 2443-2454.
-
(2012)
N Engl J Med.
, vol.366
, Issue.26
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
-
40
-
-
84976511909
-
PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
-
Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26): 2542-2552.
-
(2016)
N Engl J Med.
, vol.374
, Issue.26
, pp. 2542-2552
-
-
Nghiem, P.T.1
Bhatia, S.2
Lipson, E.J.3
-
41
-
-
84961827143
-
Phase 1 study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
-
Shimizu T, Seto T, Hirai F, et al. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Invest New Drugs. 2016;34 (3):347-354.
-
(2016)
Invest New Drugs.
, vol.34
, Issue.3
, pp. 347-354
-
-
Shimizu, T.1
Seto, T.2
Hirai, F.3
-
42
-
-
84929481482
-
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
-
PostowMA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21): 2006-2017.
-
(2015)
N Engl J Med.
, vol.372
, Issue.21
, pp. 2006-2017
-
-
Postow, M.A.1
Chesney, J.2
Pavlick, A.C.3
-
43
-
-
84944718150
-
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
-
Yamazaki N, Kiyohara Y, Uhara H, et al. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother Pharmacol. 2015;76(5): 997-1004.
-
(2015)
Cancer Chemother Pharmacol.
, vol.76
, Issue.5
, pp. 997-1004
-
-
Yamazaki, N.1
Kiyohara, Y.2
Uhara, H.3
-
44
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8): 711-723.
-
(2010)
N Engl J Med.
, vol.363
, Issue.8
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
45
-
-
84946558469
-
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes ofmetastatic melanoma
-
Zimmer L, Eigentler TK, Kiecker F, et al. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes ofmetastatic melanoma. J Transl Med. 2015;13:351.
-
(2015)
J Transl Med.
, vol.13
, pp. 351
-
-
Zimmer, L.1
Eigentler, T.K.2
Kiecker, F.3
-
46
-
-
84924543977
-
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma
-
Zimmer L, Vaubel J, Mohr P, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS One. 2015;10(3):e0118564.
-
(2015)
PLoS One.
, vol.10
, Issue.3
, pp. e0118564
-
-
Zimmer, L.1
Vaubel, J.2
Mohr, P.3
-
47
-
-
84883207410
-
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
-
Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36(7):382-389.
-
(2013)
J Immunother.
, vol.36
, Issue.7
, pp. 382-389
-
-
Le, D.T.1
Lutz, E.2
Uram, J.N.3
-
48
-
-
37349072460
-
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
-
Yang JC, HughesM, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825-830.
-
(2007)
J Immunother.
, vol.30
, Issue.8
, pp. 825-830
-
-
Yang, J.C.1
Hughes, M.2
Kammula, U.3
-
49
-
-
33847407907
-
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy
-
O'Mahony D, Morris JC, Quinn C, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res. 2007;13(3):958-964.
-
(2007)
Clin Cancer Res.
, vol.13
, Issue.3
, pp. 958-964
-
-
O'Mahony, D.1
Morris, J.C.2
Quinn, C.3
-
50
-
-
84876576574
-
A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma
-
Maki RG, Jungbluth AA, Gnjatic S, et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma. 2013; 2013:168145.
-
(2013)
Sarcoma.
, vol.2013
, pp. 168145
-
-
Maki, R.G.1
Jungbluth, A.A.2
Gnjatic, S.3
-
51
-
-
84961325991
-
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: Ameta-analysis
-
Abdel-Rahman O, ElHalawani H, Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: ameta-analysis. Future Oncol. 2016;12 (3):413-425.
-
(2016)
Future Oncol.
, vol.12
, Issue.3
, pp. 413-425
-
-
Abdel-Rahman, O.1
ElHalawani, H.2
Fouad, M.3
-
52
-
-
85011339270
-
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
-
Morganstein DL, Lai Z, Spain L, et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf). 2017;86(4): 614-620.
-
(2017)
Clin Endocrinol (Oxf).
, vol.86
, Issue.4
, pp. 614-620
-
-
Morganstein, D.L.1
Lai, Z.2
Spain, L.3
-
53
-
-
84964910725
-
A rare case of thyroid storm
-
bcr-2016-bcr-214603
-
McMillen B, Dhillon MS, Yong-Yow S. A rare case of thyroid storm. BMJ Case Rep. 2016;2016: 1136, bcr-2016-bcr-214603. doi:10.1136/bcr-2016-214603
-
(2016)
BMJ Case Rep.
, vol.2016
, pp. 1136
-
-
McMillen, B.1
Dhillon, M.S.2
Yong-Yow, S.3
-
54
-
-
84929347192
-
Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies
-
Orlov S, Salari F, Kashat L,Walfish PG. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab. 2015;100(5): 1738-1741.
-
(2015)
J Clin Endocrinol Metab.
, vol.100
, Issue.5
, pp. 1738-1741
-
-
Orlov, S.1
Salari, F.2
Kashat, L.3
Walfish, P.G.4
-
55
-
-
84980504294
-
Treatment of ipilimumab induced Graves' disease in a patient with metastatic melanoma
-
Azmat U, Liebner D, Joehlin-Price A, Agrawal A, Nabhan F. Treatment of ipilimumab induced Graves' disease in a patient with metastatic melanoma. Case Rep Endocrinol. 2016; 2016:2087525.
-
(2016)
Case Rep Endocrinol.
, vol.2016
, pp. 2087525
-
-
Azmat, U.1
Liebner, D.2
Joehlin-Price, A.3
Agrawal, A.4
Nabhan, F.5
-
56
-
-
78751559991
-
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
-
Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011; 164(2):303-307.
-
(2011)
Eur J Endocrinol.
, vol.164
, Issue.2
, pp. 303-307
-
-
Min, L.1
Vaidya, A.2
Becker, C.3
-
57
-
-
85022190469
-
Clinical features of nivolumab-induced thyroiditis: A case series study
-
Yamauchi I, Sakane Y, Fukuda Y, et al. Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid. 2017;27(7):894-901.
-
(2017)
Thyroid.
, vol.27
, Issue.7
, pp. 894-901
-
-
Yamauchi, I.1
Sakane, Y.2
Fukuda, Y.3
-
58
-
-
0038153907
-
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
-
Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100(14):8372-8377.
-
(2003)
Proc Natl Acad Sci U S A.
, vol.100
, Issue.14
, pp. 8372-8377
-
-
Phan, G.Q.1
Yang, J.C.2
Sherry, R.M.3
-
59
-
-
37349072460
-
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
-
Yang JC, HughesM, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825-830.
-
(2007)
J Immunother.
, vol.30
, Issue.8
, pp. 825-830
-
-
Yang, J.C.1
Hughes, M.2
Kammula, U.3
-
60
-
-
84899071058
-
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody
-
Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45.
-
(2014)
Sci Transl Med.
, vol.6
, Issue.230
, pp. 230ra45
-
-
Iwama, S.1
De Remigis, A.2
Callahan, M.K.3
Slovin, S.F.4
Wolchok, J.D.5
Caturegli, P.6
-
61
-
-
84995906230
-
Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series
-
Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016;186(12):3225-3235.
-
(2016)
Am J Pathol.
, vol.186
, Issue.12
, pp. 3225-3235
-
-
Caturegli, P.1
Di Dalmazi, G.2
Lombardi, M.3
-
62
-
-
84881186333
-
Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma
-
Feng Y, Roy A, Masson E, Chen TT, Humphrey R,Weber JS. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 2013;19(14):3977-3986.
-
(2013)
Clin Cancer Res.
, vol.19
, Issue.14
, pp. 3977-3986
-
-
Feng, Y.1
Roy, A.2
Masson, E.3
Chen, T.T.4
Humphrey, R.5
Weber, J.S.6
-
63
-
-
85016813132
-
Ipilimumab 10mg/kg versus ipilimumab 3mg/kg in patients with unresectable or metastatic melanoma: A randomised, double-blind, multicentre, phase 3 trial
-
Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10mg/kg versus ipilimumab 3mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18(5): 611-622.
-
(2017)
Lancet Oncol.
, vol.18
, Issue.5
, pp. 611-622
-
-
Ascierto, P.A.1
Del Vecchio, M.2
Robert, C.3
|